Multiple sclerosis (MS) is a chronic immune-mediated inflammatory disease of the brain
and spinal cord that leads to demyelination and neurodegeneration. The diagnosis is
based on the integration of the clinical presentation and paraclinical markers with
the most important being the magnetic resonance imaging (MRI). The clinical, radiological
and underlying pathology of MS is highly heterogeneous, therefore the effectiveness
of disease-modifying treatments (DMT) differs in patients. As multiple therapies are
becoming available, there is a lower threshold to accept any disease activity or worsening
and the importance to create a surrogate marker to evaluate the efficacy of the DMT
is rising. The model of “No evidence of disease activity” (NEDA) has been used as
an outcome measure for treatment response. It is based on the absence of disease activity,
which is defined, by the absence of clinical relapses, disability progression on EDSS,
and radiological activity. Our aim was to extensively review the literature about
the concept of NEDA and its different variants. We also reviewed the importance of
its use as a surrogate marker to assess the efficacy of different DMTs.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2019 Published by Elsevier Inc.
